

Fpr2^{-/-} mice developed exacerbated alcohol-associated liver disease

Josiah E. Hardesty¹, Jeffrey B. Warner^{1,2}, Ying L. Song¹, Alison Floyd¹, Craig J. McClain^{1,2,3,4,5}, Dennis R. Warner¹ and Irina A. Kirpich^{1,2,4,5,6*}


Supplemental Table S1: Metabolic Characteristics of Experimental Mice

	WT PF (n=8)	<i>Fpr2</i> ^{-/-} PF (n=5)	WT EtOH (n=10)	<i>Fpr2</i> ^{-/-} EtOH (n=8)
Initial BW, g	21.83 ± 1.21	18.18 ± 0.48 ^a	18.05 ± 0.24 ^a	18.39 ± 0.56
Final BW, g	26.20 ± 1.53	21.60 ± 0.77 ^a	22.85 ± 0.44 ^a	22.89 ± 0.83
Liver/BW, %	3.50 ± 0.15	3.99 ± 0.11 ^a	4.29 ± 0.07 ^a	3.66 ± 0.17 ^c
WAT/BW, %	2.32 ± 0.43	1.49 ± 0.24	2.16 ± 0.2	2.64 ± 0.25 ^b
Food Consumption, mL/day per mouse	*	*	13.63 ± 0.32	13.14 ± 0.50


Abbreviations: BW: body weight, WAT: white adipose tissue. * denotes that PF mice consumed the same amount of diet as their EtOH-fed counterparts. Statistical significance and comparison are denoted by the following letters: ^a: *vs* WT PF, ^b: *vs Fpr2*^{-/-} PF; ^c: *vs* WT EtOH. One-way ANOVA, *p* < 0.05.

Supplemental Table S2: qPCR Primers

Gene	Forward Primer Sequence	Reverse Primer Sequence
<i>18s</i>	CTCAACACGGGAAACCTCAC	CGCTCCACCAACTAAGAACG
<i>Pcna</i>	TGTGCCCTTGTGTAGAGT	AAAGACCTCAGGACACGCTG
<i>Ki67</i>	TCACCTGGTCACCATCAAGC	TCAATACTCCTTCCAAACAGGCA
<i>Cd163</i>	GTGCTGGATCTCCTGGTTGT	CGTTAGTGACAGCAGAGGCA
<i>Mertk</i>	GCGAGTTTGGGACGTTGGTG	ACTTCTCGGCAGTGCTCC
<i>Mrc1</i>	AGGGACCTGGATGGATGACA	AGGGAAGGGTCAGTCTGTGT
<i>Fpr2</i>	CACAGGAACCGAAGAGTGTAAG	CACCATTGAGAGGATCCACAG



Supplemental Figure S1. Liver *Fpr2* mRNA expression in WT and *Fpr2*^{-/-} mice. Data are presented as mean ± SEM.



Supplemental Figure S2. Gating strategy to measure hepatic MoMFs and the associated quantification in WT and *Fpr2*^{-/-} mice. Data are presented as mean ± SEM. The data were acquired from independent experiments using 3 individual mice from each genotype.